AVITA Medical, Inc. Stock

Equities

RCEL

US05380C1027

Biotechnology & Medical Research

Market Closed - Nasdaq 04:00:00 2024-05-02 pm EDT 5-day change 1st Jan Change
8.72 USD +0.81% Intraday chart for AVITA Medical, Inc. +5.06% -36.44%
Sales 2024 * 115M 76.49M Sales 2025 * 164M 109M Capitalization 344M 228M
Net income 2024 * -56M -37.14M Net income 2025 * -17M -11.28M EV / Sales 2024 * 2.81 x
Net cash position 2024 * 19.8M 13.13M Net cash position 2025 * 1.85M 1.23M EV / Sales 2025 * 2.09 x
P/E ratio 2024 *
-6.36 x
P/E ratio 2025 *
-32.1 x
Employees 207
Yield 2024 *
-
Yield 2025 *
-
Free-Float 99.34%
More Fundamentals * Assessed data
Dynamic Chart

Latest transcript on AVITA Medical, Inc.

1 day+0.81%
1 week+5.06%
Current month+3.81%
1 month-42.71%
3 months-48.40%
6 months-17.50%
Current year-36.44%
More quotes
1 week
8.36
Extreme 8.36
9.08
1 month
8.01
Extreme 8.01
15.66
Current year
8.01
Extreme 8.01
18.93
1 year
8.01
Extreme 8.01
21.70
3 years
4.41
Extreme 4.4102
22.49
5 years
4.41
Extreme 4.4102
55.35
10 years
3.75
Extreme 3.75
55.35
More quotes
Date Price Change Volume
24-05-02 8.72 +0.81% 188,446
24-05-01 8.65 +2.98% 185,248
24-04-30 8.4 -3.67% 145,172
24-04-29 8.72 +2.35% 189,868
24-04-26 8.52 +2.65% 285,980

Delayed Quote Nasdaq, May 02, 2024 at 04:00 pm EDT

More quotes
AVITA Medical, Inc. is a commercial-stage regenerative medicine company. The Company is a provider of regenerative medicine addressing unmet medical needs in burn injuries, full-thickness skin defects, and in skin repigmentation, such as vitiligo. Its RECELL platform a single use, stand-alone, battery operated, autologous cell harvesting device containing enzymatic and buffer solutions, sterile surgical instruments, and actuators. RECELL is used for the treatment of thermal burn wounds and full-thickness skin defects, and for repigmentation of stable depigmented vitiligo lesions. The platform technology of the RECELL System enables a thin split-thickness skin sample from the patient to be processed and prepared, producing an autologous cellular suspension called Spray-On Skin Cells. These Spray-On Skin Cells are prepared at the point of care in as little as 30 minutes, providing a new way to treat thermal burn wounds and full-thickness skin defects.
Calendar
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
13.33 AUD
Average target price
39.74 AUD
Spread / Average Target
+198.11%
Consensus